(Image: Disclosure/ Oncoclínicas)
A Oncoclinics (ONCO3) denied that he had received a proposal from Alliance of Nelson Tanure for a merger with the company, shows a document sent this Thursday (26).
- Read more: A robot that operates on the stock exchange had a performance of 276% in 9 months of operation, higher than that of the largest traders in the world
Earlier, Valor Pipeline reported that the businessman made a proposal to combine the assets.
The proposal, according to the report, is valid for 60 days, a period in which the Oncoclínicas board can decide to engage in conversation for a potential transaction or refute it. Tanure is advised by Bank of America.
The website also informs that the company will refuse negotiations for a merger with Alliança.
“It was not a formal proposal, it was an approach with a deadline, but without stamped documentation and which will not become a negotiation”, minimizes a source.
Consolidation of the healthcare sector
Amid the meltdown of shares, rumors of mergers and acquisitions of companies are popping up.
On Monday, the Dasa (DASA3) denied that he is negotiating a combination of Ímpar's oncology business, which brings together the company's and Factorwith the Oncoclinics.
Columnist Lauro Jardim said that negotiations between the companies are ongoing.
This is not a merger. But to separate the oncology area from Amil/Dasa and invest in Oncoclínicas.
In June, Dasa and Amil signed an agreement to create the Unique Hospital Servicesone joint venture (jointly controlled venture) with equal shares of 50% of the voting capital and shared control.
Dasa falls 72% and Oncoclínicas 63% in the year.